The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study Article

publication date

  • October 1, 2019

webpage

published in

start page

  • 733

end page

  • 742

volume

  • 181

issue

  • 4